Browser does not support script.
Skip to main content
Responding to the decision by NICE to recommend only one out of three potential chronic myeloid leukaemia treatments, Mike Hobday, Head of Policy at Macmillan Cancer Support, said:
'It is good news that NICE has approved Nilotinib for cancer patients with chronic myeloid leukaemia, however, it is disappointing news for patients that Dasatnib and Imatinib have been rejected. These two drugs could have the potential to improve the quality and length of life for cancer patients.
'Of the two million people living with a cancer diagnosis in the UK over 900,000 (45%) have a rarer cancer  and many of whom still aren’t able to access the drugs they so desperately need. We hope that they and others for rarer cancers turned down by NICE will be put on the priority list of the Government’s Cancer Drugs Fund.'
If you have any questions about Macmillan we would love to hear from you| .
You can also follow us| on Facebook, Twitter, Flickr or YouTube.
© Macmillan Cancer Support 2013
what are these?|